Investors-talking-discover-img

A NEW MODEL FOR BIOPHARMA COMMERCIALIZATION

Connecting diagnostic intelligence and engagement to support launch, scale and adoption.

Why invest in Diaceutics?

As biopharma pipelines shift toward more targeted, diagnostic-driven therapies, the need for diagnostic intelligence, real-world pathway insight and coordinated engagement continues to grow.

Diaceutics is positioned around this market evolution. We help biopharma teams understand where eligible patients are being missed, where diagnostic pathways are breaking down and where action can support launch, scale and adoption.

Significant & growing market opportunity
Biopharma are rapidly shifting to diagnosis-enabled healthcare to target better patient care, capture lost revenue and increase profitability
Strong competitive moat
  • Comprehensive US lab partner network
  • Proprietary multimodal healthcare data asset
  • AI-enabled and scalable DXRX platform
Compelling value proposition
  • High ROI - $100 of additional customer revenue for every $1 spent on DXRX
  • Blue-chip customers
  • More patients identified
  • Better testing & therapy adoption
High quality revenue model
  • High growth ARR business
  • Increasing multi-year revenue visibility
  • High gross margin and profitable
  • Strong balance sheet and fully funded to support growth
Proven execution
  • 18 of top 20 pharma
  • 103 therapeutic brands
  • Two Relay (PMx) commercialization engagements
  • Proven commercial execution
  • Founder led management
105 %
Net Revenue Retention (NRR)
24 %
Revenue growth (constant currency basis)
82 %
Gross profit margin
0.3 M
Profit before tax

Financial Highlights

Annual Recurring Revenue (ARR)
19.96 M
Up 19%
Gross Profit
31.48 M
Up 11%
Adjusted EBITDA
7.57 M
Up 80%

Who are Diaceutics?

Diaceutics is the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies. We help biopharma teams find eligible patients earlier, understand where diagnostic pathways break down and act while treatment decisions are still forming. Powered by near-real-time diagnostic data, AI-enabled pathway intelligence and commercialization expertise, Diaceutics turns complex signals into coordinated action across pre-launch, launch and in-market growth. With the scale to support more than 700 therapies, we help close the gap between scientific innovation and what patients experience in the real world.

2-person
2-person

INVESTOR ENQUIRIES

Whether you are an existing shareholder or exploring Diaceutics for the first time, our investor relations team can help you find the information you need.

EXPLORE INVESTOR RESOURCES

Results and presentations
Access the latest reports, results materials and investor presentations.
VIEW RESULTS
Regulatory news
Read the latest regulatory announcements from Diaceutics.
VIEW RNS
Investor tools
Find share price information, shareholder details and analyst coverage.
VIEW TOOLS